Top line results from pivotal Phase 3 trial with roluperidone in negative symptoms in patients diagnosed with schizophrenia on track for release in second quarter WALTHAM, Mass. , May 04, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company
Management to host conference call WALTHAM, Mass. , April 27, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release
Call at 8:00 a.m. Eastern Time on Tuesday, March 31, 2020 WALTHAM, Mass. , March 24, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies addressing high unmet medical needs in the treatment of
WALTHAM, Mass. , March 12, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat unmet medical needs of central nervous system (CNS) disorders, wishes to address a sharp reduction
Company confirms timing of expected top-line results from Phase 3 roluperidone trial in Q2 2020 Management to host conference call today at 8:30 a.m. Eastern Time WALTHAM, Mass. , March 09, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical
Management to host conference call WALTHAM, Mass. , March 02, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release
Breakfast meeting to be held on Friday, March 6, 2020 in New York WALTHAM, Mass. , Feb. 28, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat unmet medical needs of central
Data readout expected in the second quarter of 2020 WALTHAM, Mass. , Feb. 05, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies addressing high unmet medical needs in the treatment of central
Top-line results expected in the second quarter of 2020 WALTHAM, Mass. , Jan. 06, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies addressing high unmet medical needs in the treatment of central
MIN-117 study did not meet its primary (MADRS) and key secondary (HAM-A) endpoints MIN-117 was generally well-tolerated with a safety profile comparable to placebo Company to host conference call at 5:00 p.m. today (dial-in information below) WALTHAM, Mass. , Dec.